Contact the Editorial Desk

Editorial correspondence

Private Peptides welcomes correspondence that improves the accuracy or currency of this briefing: a citation quoted imprecisely, a new trial result for AOD-9604, MOTS-c, or retatrutide, or a regulatory update that changes a status described on this site. This is the most useful category of message this desk receives, and each one is read.

The most actionable submissions name the specific page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is updated.

Editorial mailbox: editors@privatepeptides.com

What this desk cannot do

A few categories of message fall outside what this site is built to answer. Private Peptides is a literature briefing, not a clinical service, so it cannot advise on or recommend human use of any compound discussed here; suggest a dose, schedule, or route of administration for any individual; evaluate whether a cited trial result applies to a specific person's situation; or help locate, source, or evaluate a supplier of any compound.

None of the compounds covered here is approved for self-directed human use. Readers with a clinical question should consult a licensed healthcare provider. Responses to editorial correspondence are read but not guaranteed, and the mailbox is monitored intermittently.